Cargando…

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer: pCDK2 in luminal androgen receptor TNBC

Detalles Bibliográficos
Autores principales:	Jin, Zining, Zhang, Qingfu, Wang, Chunyu, Wang, Shengli, Lin, Lin, Zou, Renlong, Sun, Ge, Zeng, Kai, Zhou, Baosheng, Tong, Yuxin, Chen, Bo, Zhao, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827805/ https://www.ncbi.nlm.nih.gov/pubmed/35838199 http://dx.doi.org/10.3724/abbs.2022083

Ejemplares similares

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation
por: Chua, Chee Wai, et al.
Publicado: (2018)

Bipotent Progenitors Do Not Require Androgen Receptor for Luminal Specification during Prostate Organogenesis
por: Shibata, Maho, et al.
Publicado: (2020)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
por: Kokontis, John M., et al.
Publicado: (2014)

Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells
por: Brandão, Douglas C., et al.
Publicado: (2022)

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022)

Expression of androgen receptor and its regulatory molecule Lin28 in non-luminal subtype breast cancer
por: Sa-Nguanraksa, Doonyapat, et al.
Publicado: (2020)

Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
por: Stella, Stefania, et al.
Publicado: (2023)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
Publicado: (2014)

Cyclin E as a Coactivator of the Androgen Receptor
por: Yamamoto, Ayako, et al.
Publicado: (2000)

BAP18 coactivates androgen receptor action and promotes prostate cancer progression
por: Sun, Shiying, et al.
Publicado: (2016)

Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Androgen Receptor-Positive TNBC
por: Guo, Qiaonan, et al.
Publicado: (2022)

Correction to ‘BAP18 coactivates androgen receptor action and promotes prostate cancer progression’
por: Sun, Shiying, et al.
Publicado: (2021)

AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells
por: Li, Songbin, et al.
Publicado: (2022)

More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive
por: Martorana, Federica, et al.
Publicado: (2023)

Human cytomegalovirus RNA2.7 inhibits RNA polymerase II (Pol II) Serine-2 phosphorylation by reducing the interaction between Pol II and phosphorylated cyclin-dependent kinase 9 (pCDK9)
por: Huang, Yujing, et al.
Publicado: (2022)

Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma
por: Song, Huijuan, et al.
Publicado: (2020)

Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (Total) and pCyclin B1(Ser126) in Vulvar Squamous Cell Carcinoma and Their Relations with Clinicopatological Features and Prognosis
por: Wang, Zhihui, et al.
Publicado: (2015)

Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer
por: Dagher, Elie, et al.
Publicado: (2019)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy
por: Chen, Jia-Feng, et al.
Publicado: (2019)

MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer
por: Wang, Chunyu, et al.
Publicado: (2015)

Schlafen 12 Slows TNBC Tumor Growth, Induces Luminal Markers, and Predicts Favorable Survival
por: Singhal, Sandeep K., et al.
Publicado: (2023)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

THE TOTAL LUMINOUS EFFICIENCY OF LUMINOUS BACTERIA
por: Harvey, E. Newton
Publicado: (1925)

Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells
por: Kwon, Oh-Joon, et al.
Publicado: (2020)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes
por: Olsen, Jan Roger, et al.
Publicado: (2016)

Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer
por: N. Abdalla, Ashraf, et al.
Publicado: (2020)

ER-luminal [Ca(2+)] regulation of InsP(3) receptor gating mediated by an ER-luminal peripheral Ca(2+)-binding protein
por: Vais, Horia, et al.
Publicado: (2020)

ODP441 NErbB-2 and Androgen Receptor Regulate a Gene Signature Involved in Immune Response and Favorable Outcome in TNBC
por: Elizalde, Patricia, et al.
Publicado: (2022)

Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells—identification of a novel androgen response element
por: Lanzino, Marilena, et al.
Publicado: (2010)

Luminal Ca(2+) controls activation of the cardiac ryanodine receptor by ATP
por: Tencerová, Barbora, et al.
Publicado: (2012)

Control of cardiac ryanodine receptor by sarcoplasmic reticulum luminal Ca(2+)
por: Jones, Peter P., et al.
Publicado: (2017)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression
por: Valkenburg, Kenneth C., et al.
Publicado: (2017)

Proline-Directed Androgen Receptor Phosphorylation
por: Gao, Yanfei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_l6g650k2cbtle50dv0jt7fe5je